Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy

International Journal of Clinical Practice

Volumn 61, Issue 1, 2007, Pages 45-51

  Aktaran, Şebnem ^a   Akarsu, E ^a   Erbagci I ^a   Araz, M ^a   Okumus S ^a   Kartal, M ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; RECEPTOR ANTIBODY; THYROID STIMULATING HORMONE RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIPLOPIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; EYELID; FEMALE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MOON FACE; MYALGIA; OPTIC NERVE DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SMOKING; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33847029939     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01004.x     Document Type: Article

References (26)

1. Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves' ophthalmopathy is markedly decreased measurement by the medical outcomes study instrument. Thyroid 1997; 7: 885-9.
2. Bartelena I, Pincherra A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168-9.
3. Prummel MF, Bakker A, Wiersinga WM et al. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol 2003; 148: 491-5.
4. Mourtis M, Prummel WM, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol 1997; 47: 9-14.
5. Marcocci C, Marino M, Rocchi R et al. Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy. J Endocrinol Invest 2004; 27: 272-80.
6. Nagayama Y, Izumi M, Kiriyama T. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol 1987; 116: 513-8.
7. Hiromatsu Y, Tanaka K, Sato M et al. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy. Endocr J 1993; 40: 63-72.
8. Tagami T, Tanaka K, Sugawa H et al. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy. Endocr J 1996; 43: 689-99.
9. Matejka G, Verges B, Vaillant G et al. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy. Horm Metab Res 1998; 30: 93-8.
10. Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy. Jpn J Ophthalmol 2002; 46: 563-7.
11. Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy. Am J Ophthalmol 2003; 135: 285-90.
12. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous vs. oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005; 90: 5234-40.
13. Gorman CA. The measurement of change in Graves' ophthalmopathy. Thyroid 1998; 8: 539-43.
14. Bahn RS, Gorman CA. Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 1987; 16: 391-407.
15. Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73-8.
16. Terwee CB, Dekker FW, Mourits MP et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf) 2001; 54: 391-8.
17. Park JJ, Sullivan TJ, Mortimer RH, Wagenaar M, Perry-Keene DA. Assessing quality of life in Australian patients with Graves' ophthalmopathy. Br J Ophthalmol 2004; 88: 75-8.
18. Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall K. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. BMJ 1988; 297: 1574-8.
19. Marcocci C, Bartalena L, Tanda ML et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001; 86: 3562-7.
20. Kauppinen-Makelin R, Karma A, Leinonen E et al. High dose intravenous methylprednisolone pulse therapy vs. oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand 2002; 80: 316-21.
21. Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001; 24: 152-8.
22. Abalkhail S, Doi SA, Al-Shoumer KA. The use of corticosteroids vs. other treatments for Graves' ophthalmopathy: a quantitative evaluation. Med Sci Monit 2003; 9: CR477-83.
23. Baschieri L, Antonelli A, Nardi S et al. Intravenous immunoglobulin vs. corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 1997; 7: 579-85.
24. Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000; 10: 521.
25. Utiger RD. Effects of smoking on thyroid function. Eur J Endocrinol 1998; 138: 368-9.
26. Hegedius L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy. J Endocrinol Invest 2004; 27: 265-71.